Background As a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling
pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to …

Objectives: The purpose of this meta-analysis was to evaluate the efficacy and toxicity profile
of apatinib for the treatment of advanced non-small cell lung cancer (NSCLC). Methods: We …

Objectives: Apatinib, a tyrosine kinase inhibitor which selectively inhibits vascular
endothelial growth factor receptor-2, has been shown to be beneficial to patients with a …

7548 Background: Apatinib is an oral, small molecular tyrosine-kinase inhibitor (TKI)
targeting vascular endothelial growth factor receptor (VEGFR). Phase II study has showed …

Objectives Apatinib exhibits broad-spectrum antitumor activities by selectively inhibiting
vascular endothelial growth factor receptor-2. This study evaluated the efficacy and safety of …

Background Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor
receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with …

Background: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate …

Although many strategies have been developed for non-small cell lung cancer (NSCLC),
more secondary and further treatments are needed due to drug resistance or tumor …

Background This study was designed to assess the clinical efficacy and toxicity of apatinib
(YN968D1) as third or subsequent‐line treatment for stage III/IV non‐small cell lung cancer …

Background The current regimens for advanced non-small cell lung cancer (NSCLC)
patients are deficient due to failings in standard treatments. This retrospective study aimed to …